Melinta Therapeutics to Present at Upcoming Investor Conferences
September 25 2018 - 8:00AM
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage
company discovering, developing and commercializing novel
antibiotics to treat serious bacterial infections, today announced
that Dan Wechsler, President and CEO of Melinta, will present at
the following upcoming investor conferences:
- 2018 Cantor Fitzgerald Global Healthcare Conference in New
York, NY on Monday Oct. 1 at 8:55 a.m. Eastern Time. A webcast can
be accessed from the following URL:
http://wsw.com/webcast/cantor7/mlnt/.
- Ladenburg Thalmann 2018 Healthcare Conference in New York, NY
on Tuesday Oct. 2 at 10:00 a.m. Eastern Time. A webcast can be
accessed from the following URL:
http://wsw.com/webcast/ladenburg4/mlnt/.
Live and archived webcasts of the presentations
will also be accessible from Melinta’s Investor Relations website
at http://ir.melinta.com/.
About Melinta Therapeutics
Melinta Therapeutics, Inc. is the largest pure-play antibiotics
company, dedicated to saving lives threatened by the global public
health crisis of bacterial infections through the development and
commercialization of novel antibiotics that provide new therapeutic
solutions. Its four marketed products include
Baxdela® (delafloxacin), Vabomere™ (meropenem and
vaborbactam), Orbactiv® (oritavancin), and
Minocin® (minocycline) for Injection. It also has an extensive
pipeline of preclinical and clinical-stage products representing
many important classes of antibiotics, each targeted at a different
segment of the anti-infective market. Together, this portfolio
provides Melinta with the unique ability to provide providers and
patients with a range of solutions that can meet the tremendous
need for novel antibiotics treating serious infections. Visit
www.melinta.com for more information.
For More Information:
Media Inquiries:David Belian(203) 848-6276
Investor Inquiries:Lisa DeFrancesco(908)
617-1358
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Sep 2023 to Sep 2024